Stock GXI GERRESHEIMER AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gerresheimer AG

Equities

GXI

DE000A0LD6E6

Medical Equipment, Supplies & Distribution

Market Closed - Xetra
Other stock markets
 11:41:21 2024-04-26 am EDT 		5-day change 1st Jan Change
100.5 EUR +1.31% Intraday chart for Gerresheimer AG +1.62% +6.52%
Apr. 22 GERRESHEIMER AG : Buy rating from Barclays ZD
Apr. 22 GERRESHEIMER AG : Jefferies remains its Buy rating ZD

Valuation

Fiscal Period: November 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,096 3,068 2,545 2,204 3,000 3,471 - -
Enterprise Value (EV) 1 1,995 4,029 2,855 3,312 3,924 4,463 4,439 4,376
P/E ratio 26 x 34.6 x 30.4 x 22.9 x 25 x 24.3 x 17.7 x 14.3 x
Yield 1.8% 1.28% 1.54% 1.78% 1.44% 1.33% 1.63% 1.95%
Capitalization / Revenue 1.51 x 2.16 x 1.7 x 1.21 x 1.51 x 1.63 x 1.45 x 1.31 x
EV / Revenue 1.43 x 2.84 x 1.91 x 1.82 x 1.97 x 2.09 x 1.86 x 1.66 x
EV / EBITDA 4.99 x 13 x 9.32 x 9.35 x 9.7 x 10.1 x 8.42 x 7.25 x
EV / FCF 70.3 x 83.8 x 510 x -95.8 x -116 x 214 x 44.2 x 30.8 x
FCF Yield 1.42% 1.19% 0.2% -1.04% -0.86% 0.47% 2.26% 3.25%
Price to Book 2.27 x 3.47 x 2.59 x 1.77 x 2.08 x 2.23 x 2.05 x 1.85 x
Nbr of stocks (in thousands) 31,400 31,400 31,400 31,400 34,540 34,540 - -
Reference price 2 66.75 97.70 81.05 70.20 86.85 100.5 100.5 100.5
Announcement Date 2/19/20 2/18/21 2/17/22 2/23/23 2/22/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: november 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,392 1,419 1,498 1,817 1,990 2,131 2,386 2,644
EBITDA 1 400 310.1 306.3 354.2 404.5 442.9 527.2 603.9
EBIT 1 123.8 156.5 147.4 169.3 213.4 245.8 316.2 379.3
Operating Margin 8.89% 11.03% 9.84% 9.32% 10.72% 11.54% 13.25% 14.34%
Earnings before Tax (EBT) 1 98.17 135.1 127.9 140.8 167.4 199.5 269.7 328.3
Net income 1 80.78 88.56 83.79 96.12 116.1 141.9 193.6 240.2
Net margin 5.8% 6.24% 5.59% 5.29% 5.83% 6.66% 8.12% 9.08%
EPS 2 2.570 2.820 2.670 3.060 3.480 4.140 5.662 7.022
Free Cash Flow 1 28.37 48.09 5.595 -34.59 -33.74 20.88 100.3 142.2
FCF margin 2.04% 3.39% 0.37% -1.9% -1.69% 0.98% 4.21% 5.38%
FCF Conversion (EBITDA) 7.09% 15.51% 1.83% - - 4.71% 19.03% 23.54%
FCF Conversion (Net income) 35.12% 54.3% 6.68% - - 14.71% 51.82% 59.18%
Dividend per Share 2 1.200 1.250 1.250 1.250 1.250 1.335 1.635 1.956
Announcement Date 2/19/20 2/18/21 2/17/22 2/23/23 2/22/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: november 2020 S1 2021 S1 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 666.8 679.8 436.2 370.8 444.6 815.4 473 528.7 457.8 499.6 957.4 487.9 545.2 466.1 505 526 595
EBITDA 1 - 136.1 91.2 62 90.1 151.6 90.5 112 78 107.2 185.2 100 119.3 80.9 99.4 111.2 140.2
EBIT 1 58.32 61.54 51.53 21.51 47.29 68.8 46.27 54.24 31.02 59.66 90.68 53.6 69.1 31.88 49.7 60.8 88.8
Operating Margin 8.75% 9.05% 11.82% 5.8% 10.64% 8.44% 9.78% 10.26% 6.78% 11.94% 9.47% 10.99% 12.68% 6.84% 9.84% 11.56% 14.92%
Earnings before Tax (EBT) 1 - - - - - - - - - - - 42.14 57.91 20.34 38.1 48.8 76.4
Net income 1 33.13 37.33 27.33 10.73 25.16 35.89 27.34 32.89 12.05 34.43 46.48 28.03 41.62 13.01 28.2 36.1 56.5
Net margin 4.97% 5.49% 6.27% 2.89% 5.66% 4.4% 5.78% 6.22% 2.63% 6.89% 4.86% 5.74% 7.63% 2.79% 5.58% 6.86% 9.5%
EPS 1.050 1.190 0.8700 0.3400 0.8000 1.140 0.8700 1.050 0.3800 1.050 1.450 0.8100 - - - - -
Dividend per Share - - - - - - - - - - - - - - - - -
Announcement Date 7/14/20 7/13/21 2/17/22 4/7/22 7/13/22 7/13/22 10/12/22 2/23/23 4/6/23 7/6/23 7/6/23 10/5/23 2/22/24 4/11/24 - - -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: november 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 961 310 1,108 924 992 968 905
Net Cash position 1 101 - - - - - - -
Leverage (Debt/EBITDA) - 3.1 x 1.012 x 3.129 x 2.285 x 2.24 x 1.836 x 1.499 x
Free Cash Flow 1 28.4 48.1 5.6 -34.6 -33.7 20.9 100 142
ROE (net income / shareholders' equity) 25.1% 13.7% 14.3% 8.95% 8.64% 9.89% 12.3% 13.7%
ROA (Net income/ Total Assets) 8.41% 4.71% 4.85% 3.74% 3.42% 4.26% 5.37% 6.3%
Assets 1 961 1,882 1,729 2,570 3,392 3,331 3,605 3,813
Book Value Per Share 2 29.50 28.10 31.30 39.60 41.90 45.00 49.00 54.30
Cash Flow per Share 2 6.140 7.080 6.750 - 8.830 9.010 11.00 12.60
Capex 1 165 174 206 257 328 333 304 318
Capex / Sales 11.82% 12.27% 13.78% 14.12% 16.48% 15.62% 12.75% 12.04%
Announcement Date 2/19/20 2/18/21 2/17/22 2/23/23 2/22/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Gerresheimer AG

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
100.5 EUR
Average target price
132.9 EUR
Spread / Average Target
+32.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
GERRESHEIMER AG Stock Gerresheimer AG
+6.52% 3.71B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. GXI Stock
  4. Financials Gerresheimer AG